Abstract Aim To evaluate the efficacy and safety of onceweekly subcutaneous semaglutide, a glucagonlike peptide1 (GLP1) analogue, versus oncedaily sitagliptin as addon to metformin in patients with type 2 diabetes (T2D) in a multiregional clinical trial
This may be due to its dual incretin action
On the other hand, if weight loss is your main goal and you dont have diabetes, your healthcare provider will help determine which option offers the best combination of effectiveness and tolerability for you
Personal or family history of thyroid cancer, multiple endocrine neoplasia type 2, and certain severe kidney or liver diseases may disqualify you from GLP-1 therapy
If it says no, you can try again later
Fortunately, the side effects with semaglutide and tirzepatide usually improve after your body adjusts to the medication